This Article Full Text Full Text (PDF) All Versions of this Article: 23/9/1601    most recent 01.ATV.0000085841.55248.13v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, X. P. Articles by Jiang, X.-C. Search for Related Content PubMed PubMed Citation Articles by Yang, X. P. Articles by Jiang, X.-C. Related Collections Lipids Animal models of human disease Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1601.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Increased Atherosclerotic Lesions in ApoE Mice With Plasma Phospholipid Transfer Protein Overexpression

Xiao Ping Yang; Daoguang Yan; Chunping Qiao; Rui Jie Liu; Jer-Gin Chen; Juan Li; Martina Schneider; Laurent Lagrost; Xiao Xiao; Xian-Cheng Jiang

From the Department of Anatomy and Cell Biology, State University of New York, Downstate Medical Center (X.P.Y., D.Y., R.J.L., J.C., X.C.J.), Brooklyn, NY; Department of Molecular Genetics and Biochemistry, University of Pittsburgh (C.Q., J.L., X.X.), Pittsburgh, Pa; and INSERM U498, Faculté de Médecine (M.S., L.L.), Dijon, France.

Correspondence to Xian-Cheng Jiang, PhD, Department of Anatomy and Cell Biology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203. E-mail xjiang{at}downstate.edu

Objective— Plasma phospholipid transfer protein (PLTP) is involved in the metabolism of HDL and apolipoprotein B (apoB)-containing lipoproteins. Atherosclerosis susceptibility is decreased in mice with PLTP deficiency that is associated with decreased liver production of apoB-containing lipoproteins and increase in their antioxidant. To investigate additionally the effect of PLTP on the development of atherosclerosis, we overexpressed PLTP in mice.

Methods and Results— PLTP was overexpressed in apoE knockout mice using an adenovirus-associated virus (AAV)-mediated system. Plasma PLTP activity was 1.3- to 2-fold higher in mice injected with AAV-PLTP than in mice injected with control AAV-GFP, and PLTP levels were sustained during the experiment period (4 months). We show that 2-fold increased PLTP activity results in (1) a decrease in HDL cholesterol, HDL phospholipid, and apoAI levels; (2) a decrease in vitamin E contents in total plasma and in individual lipoprotein fractions; (3) an increase in lipoprotein oxidizability as assessed by copper-induced formation of conjugated dienes; (4) an increase in autoantibodies against oxidized apoB-containing particles; and (5) an increase in atherosclerosis lesions in proximal aorta.

Conclusions— These observations indicate that elevated plasma PLTP levels constitute a novel, long-term risk factor for atherosclerosis.

Key Words: phospholipid transfer protein • apoB-containing lipoproteins • oxidation • high-density lipoprotein • atherosclerosis

This article has been cited by other articles:

				M. Moerland, H. Samyn, T. van Gent, R. van Haperen, G. Dallinga-Thie, F. Grosveld, A. van Tol, and R. de Crom Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1277 - 1282. [Abstract] [Full Text] [PDF]

				L. Shelly, L. Royer, T. Sand, H. Jensen, and Y. Luo Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice J. Lipid Res., April 1, 2008; 49(4): 773 - 781. [Abstract] [Full Text] [PDF]

				D. T. Valenta, J. J. Bulgrien, D. J. Bonnet, and L. K. Curtiss Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency J. Lipid Res., January 1, 2008; 49(1): 24 - 32. [Abstract] [Full Text] [PDF]

				M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631. [Abstract] [Full Text] [PDF]

				N. Ogier, A. Klein, V. Deckert, A. Athias, G. Bessede, N. Le Guern, L. Lagrost, and C. Desrumaux Cholesterol Accumulation Is Increased in Macrophages of Phospholipid Transfer Protein-Deficient Mice: Normalization by Dietary Alpha-Tocopherol Supplementation Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2407 - 2412. [Abstract] [Full Text] [PDF]

				R. Liu, J. Iqbal, C. Yeang, D. Q.-H. Wang, M. M. Hussain, and X.-C. Jiang Phospholipid Transfer Protein-Deficient Mice Absorb Less Cholesterol Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2014 - 2021. [Abstract] [Full Text] [PDF]

				D. Yan, M. Jauhiainen, R. B. Hildebrand, K. Willems van Dijk, T. J.C. Van Berkel, C. Ehnholm, M. Van Eck, and V. M. Olkkonen Expression of Human OSBP-Related Protein 1L in Macrophages Enhances Atherosclerotic Lesion Development in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1618 - 1624. [Abstract] [Full Text] [PDF]

				A. Wehinger, I. Tancevski, W. Schgoer, P. Eller, K. Hochegger, M. Morak, A. Hermetter, A. Ritsch, J. R. Patsch, and B. Foeger Phospholipid Transfer Protein Augments Apoptosis in THP-1-Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 908 - 915. [Abstract] [Full Text] [PDF]

				R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 578 - 586. [Abstract] [Full Text] [PDF]

				M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan, M. P. Wadsworth, D. J. Taatjes, F. C. de Beer, and N. R. Webb Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 600 - 606. [Abstract] [Full Text] [PDF]

				R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]

				M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732. [Abstract] [Full Text] [PDF]

				O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF]

				D. T. Valenta, N. Ogier, G. Bradshaw, A. S. Black, D. J. Bonnet, L. Lagrost, L. K. Curtiss, and C. M. Desrumaux Atheroprotective Potential of Macrophage-Derived Phospholipid Transfer Protein in Low-Density Lipoprotein Receptor-Deficient Mice Is Overcome by Apolipoprotein AI Overexpression Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1572 - 1578. [Abstract] [Full Text] [PDF]

				G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]

				L. K. Curtiss, D. T. Valenta, N. J. Hime, and K.-A. Rye What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 12 - 19. [Abstract] [Full Text] [PDF]

				D. Yan, M. Navab, C. Bruce, A. M. Fogelman, and X.-C. Jiang PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity J. Lipid Res., October 1, 2004; 45(10): 1852 - 1858. [Abstract] [Full Text] [PDF]

				M. Schneider, B. Verges, A. Klein, E. R. Miller, V. Deckert, C. Desrumaux, D. Masson, P. Gambert, J.-M. Brun, J. Fruchart-Najib, et al. Alterations in Plasma Vitamin E Distribution in Type 2 Diabetic Patients With Elevated Plasma Phospholipid Transfer Protein Activity Diabetes, October 1, 2004; 53(10): 2633 - 2639. [Abstract] [Full Text] [PDF]

				A. R. Tall and F. Lalanne Phospholipid Transfer Protein and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1484 - 1485. [Full Text] [PDF]